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Microparticulate Delivery Vehicles**NBy Lino Ferreira, Trevor Squier, Hyoungshin Park, Hannah Choe, Daniel S. Kohane, and
Robert Langer*During normal embryogenesis, human embryonic stem cells
(hESCs) differentiate along different lineages in the context of
complex 3D tissue structures where various growth factors
direct the differentiation process at different times. Embryoid
bodies (EBs) are frequently used as a means to achieve specific
stages of embryogenesis in vitro.[1–5] They can be formed from
hESC aggregates removed from a feeder layer and cultured in
suspension (termed regular EBs). EBs allow cell–cell interac-
tion and they can be rapidly expanded to yield differentiated
cells by the use of bioreactors.[6,7] Because of heterogeneous
size and spontaneous differentiation of EBs into the three germ
layers of the embryo including ectoderm, mesoderm, and
endoderm,[1] it is generally difficult to control their differentia-
tion. Specifically for vascular differentiation, between 2 and
10% of cells in EBs can be isolated as endothelial cells or
endothelial progenitor cells after 10–13 days of differentia-
tion.[2,3] Strategies to control the vascular differentiation of
EBs could help increase the yield of vascular cells, while
contributing to a better understanding of the different growth
factors involved in this process.
We hypothesize that the incorporation of particulate growth-
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Adv. Mater. 2008, 20, 2285–2291  2008 WILEY-VCH Verlag Gdifferentiation by increasing the growth factor concentration
within the EBs, potentially at doses and in time frames
determined by the method of manufacture of both the particles
andEBs. In addition, the local delivery of growth factors within
these 3D cellular structures will likely extend the duration of
exposure of cells to the growth factors, which otherwise tend
to have short half-lives.[8] Previously, nerve-growth-factor-
releasing particles assembled with fetal brain cells have been
reported to enhance cell survival and functionality; however,
the role of these particles in cell differentiation was unclear.[9]
Another advantage of incorporating particles with EBs is that
it ensures that the cells and the drug delivery system will be
implanted together and subsequently stay together after
placement in vivo.
Here we present a novel methodology to enhance the
vascular differentiation of hESCs by the incorporation of
growth-factor-releasing particles in EBs. We demonstrate that
the incorporation of these particles has a minimal effect on cell
viability and proliferation but a large impact on differentiation.
In some cases, the effect on vascular differentiation of particles
containing growth factors was superior to that observed by
exposing EBs to large extrinsic doses of the same growth
factors. In addition, we studied the intracellular trafficking of
particles of different sizes within hESCs. We further demon-
strate that nanoparticles can be taken up by hESCs and will
accumulate in the perinuclear region.
To form EBs with a defined size we deposited between
15000 and 60000 hESCs in round-bottomed, low-adherence, 96
well plates and induced aggregation by centrifugation.[10] EBs
with diameters between 340 and 820mm were obtained by
changing the initial seeding number of cells (Supporting
Information, Fig. S1). EBs formed by 15000 or 30000 cells
showed no significant changes in metabolic activity as measured
by a (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bro-
mide (MTT) assay for 10 days while a decrease was observed
for EBs formed by a large number of cells (above 30000;
Supporting Information Fig. S1). Based on these results, we
used 30000 cells for subsequent experiments and the resulting
EBs differentiated in suspension for 10 days based on previous
results in the differentiation of hESCs into the vascular
lineage.[2]
We used biocompatible and biodegradable poly(lactide-
co-glycolide) (PLGA) particles with different sizes as a model
system to design growth-factor-releasing systems (Fig. 1A and
Supporting Information Table S1). We evaluated the mor-
phology and degradation of these particles at physiologic pHmbH & Co. KGaA, Weinheim 2285
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Figure 1. Preparation and viability of EBs containing particles. A) Scanning electron microscopy of particles 25mm (A.1, A.2), 6mm (A.3, A.4), and
0.24mm (A.5, A.6) at day 0 (A.1, A.3, A.5) and 10 (A.2, A.4, A.6), after incubation in PBS at 37 8C. B) Scheme for the formation of EBs containing particles.
1) Undifferentiated hESC colonies were dissociated into single cells which were aggregated with particles of different sizes in a 96 well-plate by
centrifugation forming EBs. 2) After 2 days, EBs were transferred to a low adhesion 24-well plate and cultured for additional 8 days in differentiation
medium. 3) EBs were then characterized by immunocytochemistry and quantitative RT-PCR. C) Size of EBs (average S.D., n¼ 13) formed by the
aggregation of 30000 cells in the presence or absence of different concentrations of PLGA particles. D) Distribution of TRITC-labeled particles with different
sizes in EBs at different depths, as evaluated by confocal microscopy. EBs were formed by the aggregation of 30000 hESCs and 0.15mg mL1 of particles.
Bar corresponds to 100mm. E) Mitochondrial metabolic activity (average S.D., n¼ 6) of EBs formed by the aggregation of 30000 hESCs and different
concentrations of particles with different size, at day 2 and 10. The absorbances at 540 nm were normalized by control day 2 absorbance.
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release. After 10 days in PBS, small-size microparticles (6mm)
kept their initial surface morphology while the surface of large
microparticles (25mm) underwent degradation. Nanoparticles
(0.24mm) showed substantial aggregation and disruption of
their spheroid geometry compared to the larger particles.
Particles 25mm, 6mm, and 0.24mm in size showed a mass loss
of 12%, 22%, and 24% over 10 days, respectively.
To incorporate particles in theEBswe deposited 30000 hESCs
and different concentrations of particles (0.15 and 0.06mg of
particles per mL of differentiation medium) in a 96 well plate
and forced their aggregation by centrifugation (Fig. 1B). At
day 2, the diameters of the EBs incorporating different particle
sizes were not statistically different (n¼ 13, P> 0.05) from
thosemade without particles (Fig. 1C). EBs were transferred at
day 2 to a 24 well-plate in order to remove the particles that
were not incorporated (around 20–30%; Fig. 1B). Next, we
evaluated the distribution of particles incorporated in the EBs.
Particles were distributed across the constructs with higher
frequency in the center (Fig. 1D). Particles 6mm and 0.24mm
in size showed aggregation in EBs, but 20mm particles did not.Figure 2. Cellular uptake of particles. A) Flow cytometry analyzes of particle u
uptake of particles is observed for particles 6 and 25mm in size, while substan
cellular uptake of nanoparticles EBs were formed by the aggregation of 30000 h
lysosensor indicates endosomes, green phalloidin indicates cytoplasm, and TR
co-localized with endosomes as a yellow color and distributed mainly in the
Adv. Mater. 2008, 20, 2285–2291  2008 WILEY-VCH VerlThe cytotoxicity of PLGA particles incorporated in EBs was
assessed by a Live–Dead assay after 2 days of EB formation.
Cell viability was above 80%, and no significant differences
were observed among the different conditions tested (Support-
ing Information Fig. S2). As assessed by anMTT assay at day 2,
the metabolic activity in EBs with particles was not statistically
significant (n¼ 6, P> 0.05) to the one observed in EBs without
particles (Fig. 1E). Moreover, no statistically significant
increase (n¼ 6, P> 0.05) in cellular metabolic activity was
observed over 10 days (Fig. 1E), suggesting that EBs were in a
non-proliferative state, conducive to differentiation. Taken
together, our results indicate that PLGA particles had little
effect on the viability of EBs.
Previous studies have shown that particles up to 1mm can be
internalized by receptor-mediated endocytosis by some cell
types.[11–14] Particle uptake by hESCs at different stages of
differentiation is largely unknown, as is their final cellular
localization. We studied cellular uptake of fluorescent-labeled
PLGAparticles of different sizes by fluorescence-activated cell
sorting (FACS; Fig. 2A). For this purpose, EBs with or without
tetramethylrhodamine-5-(and-6)-isothiocyanate (TRITC)-labelledptake. Quantification of TRITC-positive cells indicated that minimal cellular
tial cellular uptake is observed for nanoparticles. B) Confocal microscopy of
ESCs and 0.15mgmL1 of particles. Blue Topro-3 stains the nucleus, green
ITC-labelled nanoparticles are displayed in red. Nanoparticles can be seen
perinuclear region. For all pictures, the scale bar corresponds to 20mm.
ag GmbH & Co. KGaA, Weinheim www.advmat.de 2287
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2288particles at concentrations between 0.03mg mL1 and
0.15mg mL1 were dissociated at day 2, the cells plated in a
24 well plate for 18 h, washed to remove loosely bound
particles, and characterized by FACS. Nanoparticles (0.24mm
in size) were highly taken up by cells. Increasing the initial dose
of nanoparticles in EBs resulted in a higher mean fluorescence
intensity as well as an increased fraction of the cell population
associated with the fluorescence, indicative of particles with the
cells (Fig. 2A). At the highest dose of 0.15mg mL1, over 90%
of the population was positive for the nanoparticles. Our FACS
results further show that 6 and 25mm microparticles were
rarely taken up by cells since only 13% of the cell population
was positive for the microparticles.
Confocal microscopy was performed to confirm that PLGA
nanoparticles were located intracellularly, instead of adsorbing
onto the cell surface and to identify the exact intracellular
location following internalization. For this purpose, EBs
incorporating fluorescent-labeled particles at a concentration
of 0.15mg mL1 of differentiation medium were dissociated at
day 2, the cells plated in a 24 well plate for 18 h, fixed, and then
labeled either with phalloidin to stain cellular actin or lyso-
Sensor green to stain endosomes (Fig. 2B). Images of hESCs
reconstructed from z-stacks of confocal images indicated
extensive cellular uptake of nanoparticles (Fig. 2B) and low
uptake of microparticles (Supporting Information Fig. S3).
Particles taken up by hESCs were in general localized in the
perinuclear region. This agrees with other reports showing
perinuclear accumulation of nanomaterials in primary cells[14]Figure 3. Growth-factor release in microparticles and protein expression in E
VEGF165, PlGFand bFGF. B) EBs at day 2 and 10 containing PlGF-releasing mic
endothelial (Flk-1, CD34 and PECAM1) markers in EBs containing PlGF-
a-fetoprotein co-staining was also performed to assess the differentiation of EB
www.advmat.de  2008 WILEY-VCH Verlag GmbH &or mesenchymal stem cells.[15] Furthermore, our results show
thatmost of the particles were localized in endosomes as shown
by the co-localization of the particles with the lysoSensor green
staining. We further characterized the cellular uptake of
nanoparticles in EBs by transmission electron microscopy
(TEM) analyses. TEM results confirm that nanoparticles are
taken up by hESCs in EBs (Supporting Information Fig. S4).
Regulatory factors that are known to contribute to early
vascular development include vascular endothelial growth
factor (VEGF165),
[16] basic fibroblast growth factor (bFGF),[17]
and placenta growth factor (PlGF).[18] VEGF165 mediates its
responses primarily by activating Flt-1 (also called VEGF-R1)
and Flk-1/KDR (also called VEGF-R2).[19] PlGF and bFGF
mediate their effects through Flt-1 and FGF receptor tyrosine
kinases, respectively.[19] The three receptors are expressed in
EBs at early stages of differentiation and in some cases in
undifferentiated hESCs.[2,20] Since these receptors are loca-
lized at the surface of cells, growth factor release should be
extracellular. Therefore, microparticles of 6mm in size were
selected for subsequent experiments. These particles are mini-
mally taken up by cells compared to nanoparticles, and they are
more highly dispersed in composite EBs than 25mm particles
and may therefore produce a more homogeneous differentia-
tion. We characterized the release kinetics of PLGA particles
loaded with growth factors (Fig. 3A). Quantitative differences
in the cumulative mass of growth factor released from the
particle preparations were observed (Fig. 3A and Supporting
Information Table S2). The release kinetics of all three growthBs containing growth factor-releasing microparticles. A) Release profile of
roparticles. Bar corresponds to 200mm. C) Localization and organization of
releasing microparticles, as evaluated by confocal microscopy. Nestin/
s into the ectoderm and endoderm germ layers. Bar corresponds to 50mm.
Co. KGaA, Weinheim Adv. Mater. 2008, 20, 2285–2291
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by a slow or negligible release. After 10 days, 1mg of particles
had released 7.6, 4.5, and 1.5 ng of PIGF, VEGF and bGFG,
respectively, corresponding to the release of 20%, 10%, and
5% of the initial amount of encapsulated growth factor. Pre-
viously, we have shown that VEGF released from this particle
formulation was functional, as assessed by a cell survival
assay.[21]
We then incorporated these growth-factor-containing
particles in EBs for 10 days (Fig. 3B) and characterized the
vascular differentiation of the EBs at the protein and gene
levels, compared to constructs containing blank particles. For
each EB we used 25mg of microparticles, which corresponds to
approximately 195000 particles as measured with a hemocyto-
meter (see Experimental). Since roughly 70% of the particles
initially used in each well were incorporated in the EBs, this
corresponds to approximately 136500 particles or a mass of
17.5mg per EB. The genes and proteins analyzed included
endothelial cell adhesionmolecules such as PECAM1, vascular
endothelial-cadherin (VE-cad) and CD34; growth factor recep-
tors such as vascular endothelial growth factor receptor-2 (Flk-1/
KDR) and Tie-2; endothelial glycoproteins such as von Will-
ebrand factor (vWF) and secreted endothelial molecules
including angiopoietin 2 (Ang2)[3] Immunofluorescence studies
showed that of the three endothelial cell markers assessedFigure 4. Endothelial differentiation on regular EBs or EBs containing gro
containing growth factor- releasing microparticles (A; EBs) and regular EBs (B;
colonies of undifferentiated hESCs from the feeder layer and let them in suspen
the forced aggregation of single hESCs and microparticles. In both cases, RN
analysis. Quantification of target genes was performed relatively to the referenc
EBs with blank particles or REBs cultured without growth factors. *, **, a
respectively).
Adv. Mater. 2008, 20, 2285–2291  2008 WILEY-VCH Verl(PECAM1, CD34, and Flk-1/KDR), Flk-1/KDR was the highly
expressed in all the conditions tested, particularly in EBs
containing VEGF- releasing particles (approximately 40–50%of
the cells displayed this marker; Fig. 3C and Supporting
Information Fig. S4). Below 10% of cells in EBs expressed
PECAM1 and CD34 markers.
Figure 3C shows the localization and organization of end-
othelial markers in EBs containing PlGF particles. CD34þ and
PECAM1þ cells seemtoorganize in vascular networks, as previously
reported by us in regular EBs,[2,21] while KDR/Flk-1þ cells are
randomly organized. Similar results were obtained for the
remaining composite EBs (Supporting Information Fig. S4).
We then evaluated at the gene level the differentiation of
EBs. VEGF, PlGF, and bFGF microparticles improved the
vascular differentiation of EBs, as 3–5 of the 7 genes are
up-regulated as compared to EBs containing blank particles
(Fig. 4A). PlGF seems to have a greater effect than the other
two growth factors under the conditions tested. We then
compared the gene expression of EBs-containing growth-
factor-releasing particles and EBs formed by a regular
approach (regular EBs), that is, formed by the removal of
hESC colonies from a feeder layer and exposed to medium
supplemented with each of growth factors (50 ng mL1) for
10 days (Fig. 4B). The vascular differentiation effect of VEGF
in these regular EBs was higher than the one observed in EBswth factor-releasing microparticles. Endothelial gene expression in EBs
REBs) as assessed by quantitative RT-PCR. REBs were formed by removing
sion. EBs containing growth factor-releasing microparticles were formed by
A was isolated at day 10 during differentiation and subjected to RT-PCR
eGAPDHgene, and normalized to the expression of the differentmarkers in
nd *** denote statistical significance (P< 0.05, P< 0.01, and P< 0.001,
ag GmbH & Co. KGaA, Weinheim www.advmat.de 2289
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2290containing VEGF microparticles. Surprisingly, although EBs
containing bFGF or PlGF microparticles were exposed to
lower concentrations of growth factors than EBs exposed
to exogenous factors (for bFGF approx. 175 pg mL1 vs.
50 ng mL1 and for PlGF approx. 887 pg mL1 vs. 50 ng mL1)
the vascular differentiation was comparable or even superior.
For example, the expression of PECAM-1, a definitive marker
for endothelial cells,[2,17] was two or four-fold higher in EBs
containing bFGF or PlGF microparticles than regular EBs
exposed to those growth factors, respectively. Therefore our
results show that the release of small concentrations of growth
factors by microparticles within EBs contributed largely to
their vascular differentiation.
We assessed whether the growth-factor-releasing particles in
EBs could limit their differentiation toward other germ layers
(i.e., ectoderm and endoderm germ layers). For that purpose
we evaluated the expression of genes and proteins related to
neuronal differentiation (ectodermal differentiation) including
nestin and neurofilament 68 Kd,[4,7,21] and markers related to
hepatic differentiation (endodermal differentiation) including
albumin and a-fetoprotein.[7,21] PlGF microparticles in EBs
substantially reduced the neuronal and hepatic differentiation
of cells as compared to EBs containing blank microparticles
(Fig. 3C and Supporting Information Fig. S5), and this effect
was greater than in regular EBs exposed to PlGF. In addition,
bFGF microparticles in EBs substantially reduced the hepatic
but not the neuronal differentiation, while VEGF micro-
particles incorporated in EBs have no effect in the hepatic
differentiation and variable effect in the neuronal differentia-
tion (Supporting Information Figs. S4 and S5).
In summary, we report a simple methodology to control the
differentiation of hESCs into the vascular lineage. Vascular
cells are very promising for tissue engineering applications and
the treatment of cardiovascular diseases such as myocardial
ischemia.[22] Our approach uses biodegradable and biocom-
patible components and allows for the control of several
variables of potential importance for cell differentiation
including growth factor concentration, spatial positioning of
growth factor and combinatorial release of bioactive mole-
cules. This platform can likely be extended to the differentia-
tion of hESCs into other cell lineages.
Experimental
Preparation of Growth-Factor-Releasing Particles: Particles were
prepared using a double emulsion solvent evaporation procedure. For
nanoparticles, PLGA (100 mg, inherent viscosity 0.16–0.24 dl g1,
Boehringer Mannheim) polymer was dissolved in ethyl acetate (1mL,
Aldrich) with magnesium hydroxide (4mg, Aldrich). Then, 50mL of an
aqueous solution of BSA (50mgmL1 BSA in 10mM phosphate buffer,
pH 7.4 containing 5mg of heparin) was added to the organic polymer
solution, and the aqueous and organic phases were emulsified by
sonication (Vibra Cell, Sonics & Materials, Inc., Danbury, CT). For
microparticles 6 and 25mm, PLGA (100 mg, inherent viscosities of
0.16–0.24 or 0.32–0.44 dl g1) polymer (see Supporting Information
Table S1) was dissolved in methylene chloride (2mL, Aldrich) with
magnesium hydroxide (4mg). Then, 50mL of PIGF or bFGF orwww.advmat.de  2008 WILEY-VCH Verlag GmbH &VEGF165 (R&D Systems) (5mg; in 50mg mL
1 BSA in 10mM
phosphate buffer, pH 7.4 containing 5mg of heparin) or BSA solution
was added to the organic polymer solution, and the aqueous and
organic phases were emulsified by sonication (Vibra Cell, Sonics &
Materials, Inc., Danbury, CT). For the preparation of fluorescence-labeled
particles, 20mL of a tetramethylrhodamine-5-(and-6)-isothiocyanate
(TRITC; Molecular Probes; 10mg mL1 in ethyl acetate or methylene
chloride) was added to the organic phase of each formulation,
maintaining the other components. Microparticles and nanoparticles
were prepared and characterized as previously described [23] and
stored at 20 8C. The morphology of PLGA particles during growth
factor release was evaluated by scanning electron microscopy (SEM).
For that purpose, they were mounted onto an aluminum stud, and gold
coated by plasma vapor deposition. To determine the density of
particles 6mm, 2.5mg of microparticles were suspended in 1.25mL of
PBS after which a small volume of this solution was loaded into a
hemocytometer, visualized using a phase contrast microscope (40),
and counted. This procedure was repeated for at least two different
batches to yield an overall estimate of 7.8 106 (9.5% S.D.)
microparticles mg1 powder.
Growth Factor Release Studies: Microparticles (10 mg) were placed
in PBS (0.5 mL) and incubated under mild agitation, at 37 8C. At
specific intervals of time, the particle suspension was centrifuged (at
4,000 rpm for 2min) and 0.4mL of the release medium removed and
replaced by a new one. The reserved supernatant was stored at 20 8C
until the growth factor content in release samples was assessed using an
enzyme-linked immunosorbent assay (ELISA; R&D Systems). Con-
centrations of growth factors were determined by comparison to a
standard curve. All analyses were conducted in duplicate. To
determine the loading efficiency of PLGA particles, 2.5mg of micro-
particles were dissolved in 0.5mL of 1N NaOH overnight and the
absorbance measured at 284 nm. The results are expressed as a
percentage of the ratio of protein encapsulated to total protein used.
hESC Culture and Formation of EBs: Undifferentiating hESCs
(H9, passages 25 to 50; WiCell, Wisconsin) were grown on an
inactivated mouse embryonic fibroblast (MEF) feeder layer, as
previously described [2,21]. To induce the formation of EBs,
undifferentiated hESCs were treated with 2mg mL1 type IV
collagenase for 1–2 h, and then transferred (2:1) to low attachment
plates (Ø¼ 10 cm, Corning) containing 10mL of differentiation
medium (80% knockout-Dulbecco’s Modified Eagle Medium, supple-
mented with 20% fetal bovine serum (FBS, Invitrogen), 0.5%
L-glutamine, 0.2% b-mercaptoethanol, and 1% nonessential amino
acids (all from Invitrogen)). The EBs obtained by this procedure are
named regular EBs. They were cultured for 10 days at 37 8C and 5%
CO2, in a humidified atmosphere, with changes of media every 2–3
days. To assess the effect of bFGF, PlGF, and VEGF165 in the
differentiation profile of EBs, the differentiation medium was
supplemented with 50 ng mL1 of growth factor.
Preparation of EBs Containing Nano- and Microparticles: Undiffer-
entiated hESCs seeded onMEFS were treated with 2mgmL1 type IV
collagenase for 2 h, washed in PBS, then treated with cell dissociation
solution for 10 minutes and dissociated by gentle pipetting. EB
formation was induced by seeding the desired number of hESCs
in 168.5mL of differentiation medium containing 0.15 or 0.06 or
0.03mg mL1 of particles in each well of 96 well, round-bottomed,
low-attachment plates (Nunc, Denmark). The plates were then
centrifuged at 1200 g for 4 minutes to aggregate the cells. At day 2,
the formed EBs were removed from the 96 well-plate and placed in a
low-adherent 24 well plate (4–6 EBs per well). The differentiation
medium was changed every 2–3 days.
Viability and Metabolic Activity of EBs Containing Particles: Cell
viability of EBs containing particles was determined using a LIVE/
DEAD kit (Molecular Probes) containing calcein AM (2mg mL1, in
PBS) and ethidium homodimer (4mg mL1, in PBS). The EBs were
placed in the kit solution for 20min and visualized under a Zeiss LSM
510 confocal microscope. This kit measures the membrane integrity ofCo. KGaA, Weinheim Adv. Mater. 2008, 20, 2285–2291
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with intracellular esterase, whereas non-viable cells fluoresce red due
to the diffusion of ethidium homodimer across damaged cell
membranes and binding with nucleic acids.
The metabolic activity of EBs containing particles was measured
through a MTT assay after 2 and 10 days of culture. The MTT solution
(0.2mL, 0.45mg mL1 in differentiation medium) was added to each
well (96 well plate) containing ca. 6 EBs for 3 h, at 37 8C. After that
time, the medium was removed and 0.1mL of DMSO was added for
15min. The absorbance was then measured spectrophotometrically at
540 nm.
FACS Analysis: EBs differentiated for 2 days were treated with
trypsin (0.25% in PBS) for 5 minutes and dissociated by gentle
pipetting. Single cells were plated in a 1% gelatin-coated 24 well
plate (1 105 cells well1) containing differentiation medium. After
18 h, the cells were washed with PBS and dissociated with trypsin. The
single cell suspensions were then analyzed on a FACScan (Becton
Dickison), using a CellQuest software.
Confocal Microscopy Analysis: At day 10 of differentiation, EBs
containing particles were transferred to gelatin-coated cover slips with
differentiation medium, allowed to attach overnight, and then, fixed
with 4% (w/v) paraformaldehyde for 30 minutes at room temperature.
To evaluate the distribution of TRITC-labelled particles within EBs,
the cell nuclei were stained with Topro-3 (Sigma) followed by the
examination with a Zeiss LSM 510 confocal microscope.
To evaluate endothelial marker expression in EBs containing
growth factor-releasing particles, fixed EBs were blocked with 3%
BSA solution, and the cells stained for 1 h with the following
anti-human primary antibodies: PECAM1 (Dako), CD34 (Dako),
Flk-1/KDR (Santa Cruz Biocehmicals), nestin (R&D Systems) and
a-fetoprotein (Dako). In each experiment, an isotype-matched IgG
control was used. Binding of primary antibodies to specific cells was
detected with anti-mouse IgG Cy3 conjugate, anti-rabbit IgG Cy3
conjugate or anti-mouse IgG FITC (all from Sigma). Cell nuclei were
stained with Topro-3 and the slides examined by confocal microscopy.
To evaluate the cellular uptake of particles, EBs containing particles
and differentiated for 2 days were dissociated by trypsin (0.25% in
PBS) and plated (1 105 cells/well) in a 1% gelatin-coated chamber
slides containing differentiation medium for 18 h. For lysosensor
staining, cells were stained with lysosensor green (2mM in differentia-
tion medium; Molecular Probes) for 1 h, washed with PBS, and then
fixed with 4% (w/v) paraformaldehyde for 15 minutes at room
temperature. Cell nuclei were stained with Topro-3 (0.002%, v/v, in
PBS) for 30min. For phalloidin staining, cells were fixed with 4% (w/v)
paraformaldehyde for 15 minutes at room temperature, washed with
PBS, permeabilized with 0.1%Triton X-100 in PBS, washed again with
PBS and finally stained with 50mg mL1 FITC-phalloidin (Sigma) for
30 minutes at room temperature. The stained cells were then washed
with PBS and cell nuclei stained with Topro-3.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Analysis: Total RNA from regular EBs or EBs containing micro-
particles (3–4 separate experiments and combined in equal amounts)
was isolated with RNeasy Minikit (Qiagen, Valencia). cDNA was
prepared from 1mg total RNA using Taqman Reverse transcription
reagents (Applied Biosystems, CA). Quantitative PCR (qPCR) was
performed using Power SYBR Green PCR Master Mix (Applied
Biosystems) and the detection using a 7500 Fast Real-Time PCR
System (Applied Biosystems, Foster). Quantification of target genes
was performed relatively to the reference GAPDH gene: relative
expression¼ 2[–(CtCtsampleÞGADPH. The mean minimal cycle threshold
values (Ct) were calculated from quadruplicate reactions. Then, the
relative gene expression for EBs containing growth factor-releasing
microparticles was normalized to the relative gene expression found inAdv. Mater. 2008, 20, 2285–2291  2008 WILEY-VCH VerlEBs containing blank particles. Primer sequences are published as
Supporting Information (Supporting Information Table S3).
Statistical Analysis: An unpaired t test or one-way analysis of
variance with Bonferroni post test was performed for statistical tests by
using GraphPad Prism 4.0 (San Diego, CA). Results were considered
significant when P 0.05.
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